Compare GTY & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTY | PHVS |
|---|---|---|
| Founded | 1955 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | 1998 | 2020 |
| Metric | GTY | PHVS |
|---|---|---|
| Price | $36.09 | $34.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $32.60 | ★ $41.82 |
| AVG Volume (30 Days) | 533.0K | ★ 566.0K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.92% | N/A |
| EPS Growth | ★ 8.00 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $221,727,000.00 | N/A |
| Revenue This Year | $9.39 | N/A |
| Revenue Next Year | $7.83 | N/A |
| P/E Ratio | $83.93 | ★ N/A |
| Revenue Growth | ★ 9.02 | N/A |
| 52 Week Low | $25.39 | $19.12 |
| 52 Week High | $36.12 | $36.60 |
| Indicator | GTY | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 73.33 | 57.18 |
| Support Level | $32.41 | $24.73 |
| Resistance Level | N/A | $36.60 |
| Average True Range (ATR) | 0.58 | 1.64 |
| MACD | 0.18 | -0.14 |
| Stochastic Oscillator | 87.54 | 54.17 |
Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.